Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Annayyaon Nov 06, 2020 1:50pm
94 Views
Post# 31852540

RE:Biogen's success has nothing to do with PMN

RE:Biogen's success has nothing to do with PMNThere's also phase 2 which totals $3 million and expected to close within a week, so the money will last us a few months, maybe 6 months. What's interesting is the list of things this company has lined up including near term revenue generating opportunities. The clause of the 60 cents for 30 days forcing the warrants to be exercised is good to see with the hope that the company delivers on its promises and increases shareholder value soon enough to prevent another low priced PP. A PP was expected based on the cash on hand in the last financial statement so it wasn't surprising, it's just that they did it at 12 cents which I didn't like.
Actuarial wrote: How long would $1.6M last? One month? Two months? I can see another PP is on its way ......


<< Previous
Bullboard Posts
Next >>